SCHEMBL31099271

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C

nearest known ligand 0.84

Predicted protein targets (top 1)

	gene	UniProt	supporting neighbours	confidence
▸	GLP1R	P43220	20/20	0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29801807	1.00	GLP1R (0.84)	GLP1R
SCHEMBL29431871	1.00	GLP1R (0.84)	GLP1R
SCHEMBL29942605	1.00	GLP1R (0.84)	GLP1R
SCHEMBL28662518	1.00	GLP1R (0.84)	GLP1R
SCHEMBL29349999	0.99	GLP1R (0.84)	GLP1R
SCHEMBL31731011	0.98	GLP1R (0.83)	GLP1R
SCHEMBL29363146	0.98	GLP1R (0.83)	GLP1R
SCHEMBL29362765	0.98	GLP1R (0.83)	GLP1R
SCHEMBL29743095	0.98	GLP1R (0.81)	GLP1R
SCHEMBL27827907	0.98	GLP1R (0.83)	GLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-3452049-B1	GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF	IONIS PHARMACEUTICALS INC (US)	2026-04-01	—	—	EP	disclosed
CN-119876131-A	GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof	IONIS制药公司	2025-04-25	—	—	CN	disclosed
CN-111448207-B	GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof	IONIS制药公司	2024-11-01	—	—	CN	disclosed
US-12115225-B2	GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof	ASTRAZENECA AB (SE)	2024-10-15	—	—	US	disclosed
US-20240293563-A1	GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF	ASTRAZENECA AB (SE)	2024-09-05	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20240293563-A1	GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF	GLP1R, GIPR, GRPR	GLP1R 1/4885
US-12115225-B2	GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof	GLP1R, GIPR, GRPR	GLP1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.